Loading...
Efficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemotherapy in patients with NSCLC
Felip, E Brunsvig, P Helland, A Vinolas, N Aix, S Carcereny, E Gomez, MD Perez, JMT Arriola, E Campelo, RG
Felip, E
Brunsvig, P
Helland, A
Vinolas, N
Aix, S
Carcereny, E
Gomez, MD
Perez, JMT
Arriola, E
Campelo, RG
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Felip E, Brunsvig P, Helland Å, Viñolas N, Aix S, Carcereny E, et al. MA03.06 Efficacy Results of Selective AXL Inhibitor Bemcentinib with Pembrolizumab Following Chemotherapy in Patients with NSCLC. Journal of Thoracic Oncology. 2019;14(10):S258-S9.